Safety and efficacy of bosutinib in patients with AP and CML and ph plus ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200

被引：17

作者：

Gambacorti-Passerini, C.

Cortes, J. E.

Khoury, H. J.

Baccarani, M.

Kantarjian, H.

Chandy, M.

Besson, N.

Wang, J.

Arkin, S.

Bruemmendorf, T.

机构：

[1] Univ Milano Bicocca, Monza, Italy

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[4] Univ Bologna, Ist Ematol, Bologna, Italy

[5] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India

[6] Wyeth, Paris, France

[7] Pfizer Res, Cambridge, MA USA

[8] Univ Klinikum Aachen & Hamburg Eppendorf, Aachen, Germany

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.6509

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6509

引用

页数：1